All News
Clinical TrialApril 11, 20261
GLP-1 Agonist Lixisenatide Slowed Motor Progression in Parkinson's Disease (NEJM 2024)
Diabetes drug Lixisenatide significantly slowed motor progression in Parkinson's disease. LIXIPARK trial published in NEJM.
The LIXIPARK trial (Meissner et al., NEJM 2024) showed GLP-1 receptor agonist Lixisenatide slowed motor progression in Parkinson's disease. In 156 early PD patients, motor scores remained stable vs worsening in placebo. Effect persisted 2 months after discontinuation. Semaglutide (PADOVA trial) eagerly awaited.
Source: New England Journal of Medicine